Nanotechnology Now - Press Release: Arrowhead to Present at Upcoming Scientific Conferences

Home > Press > Arrowhead to Present at Upcoming Scientific Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.

Arrowhead to Present at Upcoming Scientific Conferences

Pasadena, CA | Posted on May 6th, 2014

Scheduled conference presentations include the following:

TIDES 2014 - Providence, RI, May 12-15

May 12, 2014 - An oral presentation titled, "Using Endosomal Escape Agents for siRNA Delivery in vivo," will be presented at the workshop entitled "In vivo Delivery of Therapeutic Oligonucleotides: Challenges, Considerations and Solutions," by David Lewis, Ph.D., Chief Scientific Officer

May 14, 2014 - An oral presentation titled, "Next Generation Dynamic Polyconjugates for siRNA Delivery in vivo," will be presented by Aaron Almeida, Ph.D., Senior Scientist II

10th International Symposium on Polymer Therapeutics - Valencia, Spain, May 19-21

May 19, 2014 - An oral presentation titled, "Polymer-Based Vehicles for siRNA Delivery in vivo," will be presented by David Rozema, Ph.D., Vice President, Chemistry

ASGCT 17th Annual Meeting - Washington, DC, May 21-24

May 21, 2014 - An oral presentation titled, "Development of an siRNA-Based Therapeutic for Chronic HBV Infection Using DPC Technology," will be presented by David Lewis, Ph.D., Chief Scientific Officer

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400

Investor Relations:
The Trout Group
Lauren Glaser
646-378-2972

Media:
Russo Partners
Martina Schwarzkopf, Ph.D.
212-845-4292